Drugs / Irinotican
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03528876 | Sep 2018 → Oct 2020 | gastroesophageal adenocarcinoma | University of Saskatchewan | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Irinotican | “6.2 FOLFIRI Drug Dosage Timing Irinotican 180 mg/m2 Day 1” NCT03528876 ↗ |